Anti-hepatoma mechanisms of ginsenoside

Abstract

Zhang Na, Feng Yinglu. Anti-hepatoma mechanisms of ginsenoside[J]. Journal of International Oncology, 2015, 42(10): 786-788.

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 69-90. ［2］ Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma［J］. Lancet, 2003, 362(9399): 1907-1917. ［3］ Guo XX, Guo Q, Li Y, et al. Ginsenoside Rh2 induces human hepatoma cell apoptosisvia bax/bak triggered cytochrome C release and caspase9/caspase8 activation［J］. Int J Mol Sci, 2012, 13(12): 15523-15535. ［4］ Park HM, Kim SJ, Kim JS, et al. Reactive oxygen species mediated ginsenoside Rg3 and Rh2induced apoptosis in hepatoma cells through mitochondrial signaling pathways［J］. Food Chem Toxicol, 2012, 50(8): 2736-2741. ［5］ Zhu GY, Li YW, Tse AK, et al. 20(S)Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells［J］. Eur J Pharmacol, 2011, 668(1-2): 88-98. ［6］ Zhang C, Liu L, Yu Y, et al. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells［J］. Mol Med Rep, 2012, 5(5): 1295-1298. ［7］ Jiang JW, Chen XM, Chen XH, et al. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway［J］. World J Gastroenterol, 2011, 17(31): 3605-3613. ［8］ Yoon JH, Choi YJ, Lee SG. Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogenactivated protein kinase signaling pathway in human hepatocellular carcinoma cells［J］. Eur J Pharmacol, 2012, 679(1-3): 24-33. ［9］ Yoon JH, Choi YJ, Cha SW, et al. Antimetastatic effects of ginsenoside Rd via inactivation of MAPK signaling and induction of focal adhesion formation［J］. Phytomedicine, 2012, 19(3-4): 284-292. ［10］ Ming Y, Chen Z, Chen L, et al. Ginsenoside compound K attenuates metastatic growth of hepatocellular carcinoma, which is associated with the translocation of nuclear factorκB p65 and reduction of matrix metalloproteinase2/9［J］. Planta Med, 2011, 77(5): 428-433. ［11］ Shi Q, Li J, Feng Z, et al. Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors［J］. Mol Med Rep, 2014, 10(4): 1779-1785. ［12］ Ho YL, Li KC, Chao W, et al. Korean red ginseng suppresses metastasis of human hepatoma SKHep1 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen activator［J］. Evid Based Complement Alternat Med, 2012, 2012: 965846. ［13］ Lee YS, Lee DG, Lee JY, et al. A formulated red ginseng extract upregulates CHOP and increases TRAILmediated cytotoxicity in human hepatocellular carcinoma cells［J］. Int J Oncol, 2013, 43(2): 591-599. ［14］ Lee JY, Jung KH, Morgan MJ, et al. Sensitization of TRAILinduced cell death by 20(S)ginsenoside Rg3 via CHOPmediated DR5 upregulation in human hepatocellular carcinoma cells［J］. Mol Cancer Ther, 2013, 12(3): 274-285. ［15］ Kim DG, Jung KH, Lee DG, et al. 20(S)Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin［J］. Oncotarget, 2014, 5(12): 4438-4451. ［16］ Li Q, Li Y, Wang X, et al. Cotreatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release［J］. Mol Carcinog, 2011, 50(10): 760-769. ［17］ Yu Y, Zhang C, Liu L, et al. Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas［J］. Exp Ther Med, 2013, 5(3): 761-766. ［18］ Kim SJ, Yuan HD, Chung SH. Ginsenoside Rg1 suppresses hepatic glucose production via AMP-activated protein kinase in HepG2 cells［J］. Biol Pharm Bull, 2010, 33(2): 325-328. ［19］ Yuan HD, Kim do Y, Quan HY, et al. Ginsenoside Rg2 induces orphan nuclear receptor SHP gene expression and inactivates GSK3β via AMPactivated protein kinase to inhibit hepatic glucose production in HepG2 cells［J］. Chem Biol Interact, 2012, 195(1): 35-42. ［20］ Wu R, Ru Q, Chen L, et al. Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22bearing mice［J］. J Food Sci, 2014, 79(7): H1430-1435.

[1]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[5]	Li Jiaxuan, Feng Yinglu.Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.
[6]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke.Diagnostic value of serum TIM-3 in patients with liver cancer[J]. Journal of International Oncology, 2022, 49(9): 537-542.
[7]	Zhang Yumin, Zhao Xianwei, He Qianjin, Chen Jieneng.Value of contrast-enhanced ultrasound combined with serum CXCL8 and CXCR2 in the evaluation of postoperative efficacy of transcatheter arterial chemoembolization for primary liver cancer[J]. Journal of International Oncology, 2022, 49(10): 592-596.
[8]	Di Weihua, Zhao Xuemei.Research progress on the relationship between DNA damage repair genes and liver cancer[J]. Journal of International Oncology, 2022, 49(10): 635-638.
[9]	Du Jiahang, Chen Dong, Chen Yaoting.Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2021, 48(9): 572-.
[10]	Han Baojun.Expression of histone acetyltransferase P300 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of International Oncology, 2021, 48(7): 415-419.
[11]	Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang.Progress of biomarkers in liver cancer[J]. Journal of International Oncology, 2021, 48(4): 241-245.
[12]	Xiong Lin, Zhang Xiuyun, Zhang Xiaoyu, Li Yue, Xu Ximing.IWR-1-endo affects the migration and proliferation of hepatocarcinoma cells by inhibiting the Wnt pathway[J]. Journal of International Oncology, 2021, 48(12): 711-715.
[13]	Liu Junguo, Zhang Jinjuan, Wang Yijun.Clinical application progress of variations in the technique of liver partition from ALPPS[J]. Journal of International Oncology, 2020, 47(8): 492-495.
[14]	Xin Ruiqiang, Song Xiaoping, Zhang Fan, Sun Ying, Wang Tao, Sun Wei.Mechanism of SUMO regulating XBP1 mediated endoplasmic reticulum stress on the progression of liver cancer[J]. Journal of International Oncology, 2020, 47(7): 397-403.
[15]	Zhao Chuanxi, Zhu Tingting, Liu Mingguo, Cao Lili.Advances of Krüppel-like factors in hepatocellular carcinoma[J]. Journal of International Oncology, 2020, 47(2): 119-122.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments